359 related articles for article (PubMed ID: 24827753)
1. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
Yeremenko N; Paramarta JE; Baeten D
Curr Opin Rheumatol; 2014 Jul; 26(4):361-70. PubMed ID: 24827753
[TBL] [Abstract][Full Text] [Related]
2. IL-17 in the immunopathogenesis of spondyloarthritis.
Taams LS; Steel KJA; Srenathan U; Burns LA; Kirkham BW
Nat Rev Rheumatol; 2018 Aug; 14(8):453-466. PubMed ID: 30006601
[TBL] [Abstract][Full Text] [Related]
3. Targeting the interleukin-23/17 axis in axial spondyloarthritis.
Paine A; Ritchlin CT
Curr Opin Rheumatol; 2016 Jul; 28(4):359-67. PubMed ID: 27152702
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for the treatment of axial spondyloarthritis.
Rademacher J; Poddubnyy D
Expert Opin Emerg Drugs; 2018 Mar; 23(1):83-96. PubMed ID: 29475394
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
Ceribelli A; Motta F; Vecellio M; Isailovic N; Ciccia F; Selmi C
Front Immunol; 2021; 12():622770. PubMed ID: 34149686
[TBL] [Abstract][Full Text] [Related]
6. The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.
Smith JA
Curr Rheumatol Rep; 2016 Jun; 18(6):33. PubMed ID: 27105640
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
8. The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?
Siebert S; McGucken A; McInnes IB
Curr Opin Rheumatol; 2020 Jul; 32(4):349-356. PubMed ID: 32412997
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab: a promising therapeutic option in spondyloarthritis.
Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory pathways in spondyloarthritis.
Hreggvidsdottir HS; Noordenbos T; Baeten DL
Mol Immunol; 2014 Jan; 57(1):28-37. PubMed ID: 23969080
[TBL] [Abstract][Full Text] [Related]
11. mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation
Chen S; van Tok MN; Knaup VL; Kraal L; Pots D; Bartels L; Gravallese EM; Taurog JD; van de Sande M; van Duivenvoorde LM; Baeten DL
Front Immunol; 2019; 10():2344. PubMed ID: 32194539
[No Abstract] [Full Text] [Related]
12. Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.
McGonagle D; Watad A; Sharif K; Bridgewood C
Front Immunol; 2021; 12():614255. PubMed ID: 33815371
[TBL] [Abstract][Full Text] [Related]
13. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
Toussirot E
Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
[TBL] [Abstract][Full Text] [Related]
14. Developments with experimental and investigational drugs for axial spondyloarthritis.
Clavel G; Boissier MC; Sigaux J; Semerano L
Expert Opin Investig Drugs; 2017 Jul; 26(7):833-842. PubMed ID: 28562100
[TBL] [Abstract][Full Text] [Related]
15. Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis.
Rossini M; Epis OM; Tinazzi I; Grembiale RD; Iagnocco A
Expert Opin Biol Ther; 2020 Jul; 20(7):787-798. PubMed ID: 32129102
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.
van Mens LJJ; van de Sande MGH; Menegatti S; Chen S; Blijdorp ICJ; de Jong HM; Fluri IA; Latuhihin TE; van Kuijk AWR; Rogge L; Yeremenko NG; Baeten DLP
Arthritis Rheumatol; 2018 Dec; 70(12):1994-2002. PubMed ID: 29869838
[TBL] [Abstract][Full Text] [Related]
18. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.
Tsukazaki H; Kaito T
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899140
[TBL] [Abstract][Full Text] [Related]
19. ILC3 in Axial Spondyloarthritis: the Gut Angle.
Mauro D; Macaluso F; Fasano S; Alessandro R; Ciccia F
Curr Rheumatol Rep; 2019 Jun; 21(7):37. PubMed ID: 31197599
[TBL] [Abstract][Full Text] [Related]
20. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
Rosine N; Miceli-Richard C
Front Immunol; 2020; 11():553742. PubMed ID: 33488572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
